Searchable abstracts of presentations at key conferences in endocrinology

ea0016s30.6 | Clinical highlights | ECE2008

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

Glintborg Dorte , Andersen Marianne , Hagen Claus , Heickendorff Lene , Hermann Anne Pernille

Background: PPARĪ³-agonist treatment may decrease bone mineral density (BMD) in postmenopausal women. The hypothesis that premenopausal women are relatively protected from mineral loss during PPARĪ³-agonist treatment has not been evaluated in clinical studies.Aim: To investigate the effect of pioglitazone on BMD and bone turnover markers in patients with polycystic ovary syndrome (PCOS).Methods: Thirty premenopausal PCOS pa...